These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16309948)

  • 1. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
    Temming K; Schiffelers RM; Molema G; Kok RJ
    Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.
    Liu S
    Mol Pharm; 2006; 3(5):472-87. PubMed ID: 17009846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.
    Liu S
    Bioconjug Chem; 2009 Dec; 20(12):2199-213. PubMed ID: 19719118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
    Dal Corso A; Pignataro L; Belvisi L; Gennari C
    Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RGD peptide-based non-viral gene delivery vectors targeting integrin α
    Fu S; Xu X; Ma Y; Zhang S; Zhang S
    J Drug Target; 2019 Jan; 27(1):1-11. PubMed ID: 29564914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of integrin α
    Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
    Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
    Wu H; Jiang J; Xu H; Li Q; Cai J
    Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenesis activities of novel peptide complexes: mitochondria-disruptive 9mer peptides conjugated with the integrin alpha V beta 3-homing cyclic RGD motif.
    Iwasaki T; Yamakawa M; Asaoka A; Kawano T; Ishibashi J
    Biosci Biotechnol Biochem; 2012; 76(11):2044-8. PubMed ID: 23132564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
    Kim JW; Lee HS
    Int J Mol Med; 2004 Oct; 14(4):529-35. PubMed ID: 15375578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
    Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
    Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.
    Yu YP; Wang Q; Liu YC; Xie Y
    Biomaterials; 2014 Feb; 35(5):1667-75. PubMed ID: 24268666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
    Danhier F; Le Breton A; Préat V
    Mol Pharm; 2012 Nov; 9(11):2961-73. PubMed ID: 22967287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
    Zhang Q; Lu L; Zhang L; Shi K; Cun X; Yang Y; Liu Y; Gao H; He Q
    Sci Rep; 2016 Feb; 6():19800. PubMed ID: 26842655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivalent effects of RGD peptides obtained by nanoparticle display.
    Montet X; Funovics M; Montet-Abou K; Weissleder R; Josephson L
    J Med Chem; 2006 Oct; 49(20):6087-93. PubMed ID: 17004722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding.
    Kubas H; Schäfer M; Bauder-Wüst U; Eder M; Oltmanns D; Haberkorn U; Mier W; Eisenhut M
    Nucl Med Biol; 2010 Nov; 37(8):885-91. PubMed ID: 21055618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides.
    Auzzas L; Zanardi F; Battistini L; Burreddu P; Carta P; Rassu G; Curti C; Casiraghi G
    Curr Med Chem; 2010; 17(13):1255-99. PubMed ID: 20166941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.
    Murugesan SR; Akiyama M; Einfeld DA; Wickham TJ; King CR
    Int J Oncol; 2007 Oct; 31(4):813-22. PubMed ID: 17786312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.